Cyclica Academic Partnership Program (CAPP)
Academic support has been essential to Cyclica's rapid growth. We have had the opportunity and privilege to work with some of the best research institutions in North America. To broaden and strengthen our collaboration with the academic community on a global scale, we have designed CAPP - Cyclica Academic Partnership Program (CAPP). With the launch of CAPP, we invite the brightest minds to join forces with us to create better drugs for human kind.
Ligand Express® Academic Polypharmacology (LEAP) Program
Ligand Express® Academic Polypharmacology (LEAP) Program is the inaugural program under the Cyclica Academic Partnership Program (CAPP). LEAP is a program for academic researchers to apply for access to Cyclica’s cloud-based platform, Ligand Express®, with the goal of increasing the impact of existing research efforts and bolstering publication(s) with novel in silico insights. Cyclica will award successful applicants with an in-kind contribution to Ligand Express® for a period of 90 days to screen up to five small molecules (200 - 800 dalton).
About Ligand Express®:
Ligand Express® is a patented and validated structure-based and AI-augmented platform that unbiasedly screens small molecules against a repository of all structurally characterized protein structures across all species in the Protein Data Bank (PDB). Learn more details about Ligand Express® here.
Privately and securely access Ligand Express® at www.ligandexpress.com through a web browser.
Input to the platform is a chemical structure - no knowledge of associated protein targets is required.
Analyze results in the highly interactive web-based interface to gain insights into mechanism deconvolution, target identification, drug repositioning, and lead prioritization.
Why should you participate?
Reposition existing molecules for new indications.
Increase the impact of your publications and generate high-value data for your next grant application.
Drive research insights to programs related to pharmaceuticals, nutraceuticals, cosmeceuticals, and phytochemicals.
Identify novel targets that can explain a biological observation in your assay (e.g. from a phenotypic screen or other biological assay).
Understand the on-/off-target polypharmacology profile of your compounds and create testable hypotheses (e.g. from a target-centric virtual screen).
Analyze your molecule's ADMET properties using Cyclica's proprietary ADMET-Prediction tool that outperforms traditional supervised learning techniques.
There is no cost involved in this application, and the application form takes 20 minutes to complete.
A shortlist of finalists will receive:
Opportunity to screen up to five small molecules over the course of 90 days.
Kickoff training session and continuous support from Cyclica’s Solutions Scientists.
Secure access to Ligand Express® for one principal investigator and one lab member to analyze results.
Top two projects will also receive:
Support in-vitro validation studies, that will be jointly designed and agreed by the PI and Cyclica, by providing relevant tool compounds or binding assays. (Note: only chemically synthesized query molecules are considered for this award.)
Collaboration for further analysis with Cyclica’s scientists.
Application opens: August 1, 2018
Submission deadline: September 30, 2018
Award Announcement: October 31, 2018
For more questions about our LEAP Award, please visit our FAQ Page.